Hausfeld leads Dutch excessive pricing claim against AbbVie

An Amsterdam-based non-profit is seeking a court declaration that AbbVie abused its dominance by overcharging the national healthcare system over €1 billion for its rheumatoid arthritis treatment drug.

Unlock unlimited access to all Global Competition Review content